Scientists Make Strides Toward Drug Therapy for Inherited Kidney Disease Research in the laboratory of Thomas Weimbs in MCDB has led to the discovery that patients with an inherited kidney disease may be helped by a drug that is currently available for other uses. The findings are published in this week's issue of the Proceedings of the National Academy of Sciences.
MCDB scientist in collaboration with Sanford-Burnham and Salk Institute scientists combine tumor-targeting peptides and nanoparticles to eliminate glioblastoma in a previously untreatable mouse model. In a study published the week of October 3 in the Proceedings of the National Academy of Sciences of the USA, a team of scientists led by Dr. Ruoslahti, combined a tumor-homing peptide, a cell-killing peptide, and a nanoparticle.
Newly diagnosed Type 2 diabetics tend to have one thing in common: obesity. Exactly how diet and obesity trigger diabetes has long been the subject of intense scientific research. A new study led by Jamey D. Marth, director of the Center for Nanomedicine, a collaboration between the University of California, Santa Barbara and Sanford-Burnham Medical Research Institute (Sanford-Burnham), has revealed a pathway that links high-fat diets to a sequence of molecular events responsible for the onset and severity of diabetes.
MCDB is proud to announce the establishment of an Emphasis in Pharmacology and Biotechnology within the M.A. degree. The proposal for the new degree was approved last week by the Graduate Council and Letters and Science Executive Committee. The new interdisciplinary Master's Emphasis is designed to take advantage of the many interdisciplinary opportunities in the fields of pharmacology and biotechnology on the UCSB campus. Students have the option of enrolling in a wide variety of courses offered through three UCSB departments, MCDB, Chemistry and Biochemistry, and Psychology.
Research from the laboratory of Thomas Weimbs in MCDB points to potential new drug therapies for patients with polycystic kidney disease. The findings, implicating the transcription factor STAT3 as a promising drug target, are published in this week's issue of the Proceedings of the National Academy of Sciences.
Studies of the small sea squirt may ultimately help solve the problem of rejection of organ and bone marrow transplants in humans, according to recent work from Professor De Tomaso's laboratory in MCDB.
Gary Wilcox is a trustee of The UC Santa Barbara Foundation and currently chairman of the board and CEO of a start-up antiviral drug discovery company, Cocrystal Discovery, Inc. Previously, he was executive vice president of ICOS Corporation in Bothell, Washington, and earlier he co-founded International Genetic Engineering, serving as its chairman, president, and CEO until its merger with XOMA Corporation in 1989. From 1974 until 1984, Wilcox was a professor of microbiology and a member of the Molecular Biology Institute at UCLA.
One of our MCDB faculty members is one of three scientists who have been named the recipients of the 11th annual Albany Medical Center Prize in Medicine and Biomedical Research. The pioneering work of these three scientists in isolating human stem cells holds great promise for the future of medicine. Prize recipient James A.
Capps, the U.S. Representative for California's 23rd congressional district, toured several research laboratories in MCDB, and talked to graduate students and postdoctoral fellows at the bench. She led a round-table discussion with professors, students and Dean Wiltzius to discuss the impact that the recently proposed drastic cuts in federal research funding would have on research at UCSB, education and the nation's future competitiveness.
"Filling the Blank," a documentary by Cable News Network featuring the research of MCDB professor Kenneth S. Kosik, was broadcast Saturday, Jan. 29.